Related Experiment Videos
[Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction]
J P Bassand1, J Cassagnes, J Machecourt
1Service de cardiologie, hôpital universitaire Saint-Jacques, Besançon.
Insights
Early thrombolytic therapy for myocardial infarction rapidly restores blood flow, significantly reducing infarct size and preserving heart function. This improves survival rates by limiting heart muscle damage.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (MI) requires prompt reperfusion to limit myocardial damage.
- Intravenous thrombolytic agents are crucial for restoring coronary artery patency during the acute phase of MI.
Purpose of the Study:
- To evaluate the efficacy of early intravenous thrombolytic therapy in acute myocardial infarction.
- To assess the impact of thrombolytic agents on infarct size, left ventricular function, and mortality.
Main Methods:
- Administration of intravenous thrombolytic agents during the acute phase of myocardial infarction.
- Assessment of arterial reperfusion rates and reocclusion.
- Measurement of infarct size and left ventricular systolic function.
Main Results:
- Early thrombolysis significantly limits infarct size and preserves left ventricular systolic function.
- Anisoylated plasminogen streptokinase activator complex (APSAC) demonstrates high reperfusion rates with low reocclusion.
- Mean infarct size reduced by 31% (36% for anterior infarcts), with significant preservation of cardiac function.
Conclusions:
- Early intravenous thrombolytic therapy is effective in limiting myocardial damage and improving outcomes in acute MI.
- APSAC offers favorable pharmacokinetic properties for achieving rapid and sustained reperfusion.
- Timely administration of thrombolytics, including APSAC, reduces mortality and preserves cardiac function post-MI.
Abstract:
The early intravenous administration of thrombolytic agents in the acute phase of myocardial infarction induces reperfusion of the artery responsible for the necrosis, thereby limiting the size of the infarct and preserving the left ventricular systolic function with consequent reduction of short- or long-term mortality. With the exception of urokinase, these effects have been demonstrated with all thrombolytic agents used so far, including streptokinase, plasminogen tissue activator and anistreplase. Owing to its special pharmacokinetic properties, the latest thrombolytic agent, formerly known as APSAC (anisoylated plasminogen streptokinase activator complex), provides a high arterial reperfusion rate with a low percentage of reocclusion. As a result, the mean size of the infarct is reduced by 31 per cent (36% in the case of anterior infarct), and the left ventricular systolic function is highly significantly preserved.